REPORT/RECOMMENDATION TO THE BOARD OF SUPERVISORS
OF SAN BERNARDINO COUNTY
AND RECORD OF ACTION
February 24, 2026
FROM
ANDREW GOLDFRACH, ARMC Chief Executive Officer, Arrowhead Regional Medical Center
SUBJECT
Title
Amendment to Agreement with AtriCure, LLC for the Purchase of Specialized Disposable Arterial Fibrillation Products
End
RECOMMENDATION(S)
Recommendation
1. Approve Amendment No. 2 to Agreement No. 24-918 with AtriCure, LLC, for the purchase of specialized disposable arterial fibrillation products, extending the term by two years for a total term of September 24, 2024 through September 23, 2028, with no change to the contract amount of $1,050,000.
2. Authorize the Purchasing Agent to execute amendments to Agreement No. 24-918 to add, replace or delete arterial fibrillation products based on product availability, value analysis approved products or cost competitiveness, to meet the needs of Arrowhead Regional Medical Center, subject to review by County Counsel.
3. Direct Arrowhead Regional Medical Center to transmit all executed amendments to add, replace, or delete products to the Clerk of the Board of Supervisors within 30 days of execution.
(Presenter: Andrew Goldfrach, ARMC Chief Executive Officer, 580-6150)
Body
COUNTY AND CHIEF EXECUTIVE OFFICER GOALS & OBJECTIVES
Provide for the Safety, Health and Social Service Needs of County Residents.
FINANCIAL IMPACT
Approval of this item will not result in the use of Discretionary General Funding (Net County Cost). The cost is funded by State Medi-Cal, Federal Medicare, private insurances, and other departmental revenue. Funding sources may change in the future pending any legislative activity related to the repeal and/or replacement of the Affordable Care Act. Adequate appropriation and revenue have been included in the Arrowhead Regional Medical Center (ARMC) 2025-26 budget and will be included in future recommended budgets.
BACKGROUND INFORMATION
Amendment No. 2 to Agreement No. 24-918 (Agreement) will extend the term of the Agreement for two additional years for a total term of September 24, 2024 through September 23, 2028.
Recommendation No. 2 will allow Purchasing to execute amendments solely for the purpose of adding, replacing, or deleting products for purchase under the Agreement due to fluctuations in market conditions. Approval of this delegated authority will assist with operational efficiency on these arterial fibrillation supplies for the Operating Room and the ability to provide continued operations for critical patient care.
On September 24, 2024 (Item No. 14), as the result of a non-competitive procurement, the Board of Supervisors (Board) approved Agreement No. 24-918 with AtriCure for the purchase of proprietary specialized disposal arterial fibrillation products used during open heart surgery, in the not-to-exceed amount of $50,000 for the period of September 24, 2024 through September 23, 2026.
On January 14, 2025 (Item No. 22), the Board approved an increase in funding allocation to
Agreement No. 24-918 in the amount of $1,000,000, from a not-to-exceed amount of $50,000 to a not-to-exceed amount of $1,050,000 to enable ARMC to purchase proprietary specialized disposable arterial fibrillation to meet increased demand for such products.
On August 5, 2025 (Item No. 16), the Board approved Amendment No. 1 to Agreement No. 24-918 to update the list of specialized disposable arterial fibrillation products available for purchase and related pricing, with no changes to the contract amount or term.
ARMC recommends approval of Amendment No. 2 as it will enable the hospital to continue to purchase the products to provide for the safety, health and social needs of county residents.
PROCUREMENT
Not applicable.
REVIEW BY OTHERS
This item has been reviewed by County Counsel (Charles Phan, Supervising Deputy County Counsel,387-5455) on January 16, 2026; Purchasing (Veronica Pedace, Buyer III, 387-2464) on January 21, 2026; ARMC Finance (Chen Wu, Finance and Budget Officer, 580-3165) on January 30, 2026; and County Finance and Administration (Jenny Yang, Administrative Analyst, 387-4884) on February 2, 2026.